SMAD3 and breast carcinoma: Zhu and colleagues used the CAGA12-luciferase reporter in breast cancer cells to study TGF-β/SMAD3 activity by measuring luminescence during tumorigenesis in vivo, whereas others created a transgenic CAGA12-luciferase mouse, studying TGF-β/SMAD3 response to injury [45,48].